Trailing-twelve-month (TTM) revenue is $413.80 Million with a year-over-year growth of (61.64%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $70,445,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $147,139,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $139,514,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q2 FY2026Period ended 2026-06-30 | $56,698,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $413,796,000 |
Current P/S: $1,817,863,406 market capitalization ÷ $413,796,000 TTM revenue = 4.39x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T18:30:10.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $56.70M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T18:32:24.443Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Government Contract | $217M | N/A | N/A | N/A | N/A | N/A |
| Grant | $258M | $949M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|
| Europe | $824M | $268M | $96M | $16M |
| North America | $194M | $30M | N/A | N/A |
| Rest of North America | N/A | N/A | $4M |
$413.80M
$413.80 Million
(61.64%)
vs. $1.08B a year ago (TTM)
+118.86%
5 Year compound annual growth rate
1 Year
(61.64%)
3 Year
(34.01%)
5 Year
+118.86%
10 Year
+36.02%
15 Year
+36.10%
20 Year
+23.32%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $1.12B | +$441.32M | +64.69% |
| 2024 | $682.16M | +$125.78M | +22.61% |
| 2023 | $556.38M | ($1.04B) | (65.20%) |
| 2022 | $1.60B | +$1.40B | +709.26% |
| 2021 | $197.58M | +$175.19M | +782.53% |
| 2020 |
TTM Growth
(61.64%)
3-Year CAGR
(34.01%)
5-Year CAGR
+118.86%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T18:32:24.443Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $427M |
| N/A |
| N/A |
| Nuvaxovid Sales | N/A | N/A | N/A | N/A | N/A | $625M |
|---|
| Product | N/A | N/A | $1.6B | $531M | $190M | $685M |
|---|
| Royalties and Other | N/A | $198M | $44M | $25M | $492M | N/A |
|---|
| Supply Sales | N/A | N/A | N/A | N/A | N/A | $60M |
|---|
| Rest of the World | $537M | $233M | $59M | $126M |
|---|
| UNITED STATES | N/A | N/A | $523M | $406M |
|---|
| $22.39M |
| +$3.73M |
| +19.97% |
| 2019 | $18.66M | ($15.63M) | (45.57%) |
| 2018 | $34.29M | +$3.11M | +9.98% |
| 2017 | $31.18M | +$15.82M | +103.06% |
| 2016 | $15.35M | ($20.90M) | (57.65%) |
